United States Market for Rheumatoid Arthritis Pharmacotherapeutics
United States Market for Rheumatoid Arthritis Pharmacotherapeutics
Changes on the Horizon with the Imminent Arrival of Novel Therapies
05-Jul-2012
North America
Description
This research service covers the United States rheumatoid arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed used on top of background standard of care. Included in the study are products of the market and products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Treatment paradigms for rheumatoid arthritis and patient flow dynamics through lines of therapy are also included. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics, and novel oral disease-modifying antirheumatic drugs (DMARDs).
Table of Contents
Research Service
- Executive Summary
- Market Overview
Total Rheumatoid Arthritis Pharmacotherapeutics Market
- External Challenges: Drivers and Restraints
- Forecasts and Trends
- Demand Analysis
- Market Share and Competitive Analysis
United States Market for Rheumatoid Arthritis Pharmacotherapeutics—Analysis by Market Segment
- TNF Inhibitor Segment Breakdown
- Non-TNF Biologics Segment Breakdown
- Novel Oral DMARDs Segment Breakdown
The Last Word
- Three Big Predictions
Appendix
- Appendix
Popular Topics
No Index | Yes |
---|---|
Podcast | No |
Author | Deborah Toscano |
Industries | Healthcare |
WIP Number | NB33-01-00-00-00 |
Is Prebook | No |